{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:08:03Z","timestamp":1779023283051,"version":"3.51.4"},"reference-count":188,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":313,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["65663"],"award-info":[{"award-number":["65663"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.csbj.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T21:43:12Z","timestamp":1605908592000},"page":"3577-3589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neurons under genetic control: What are the next steps towards the treatment of movement disorders?"],"prefix":"10.34133","volume":"18","author":[{"given":"Marian","family":"Tsanov","sequence":"first","affiliation":[{"name":"School of Medicine, University College Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"344","article-title":"Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease","volume":"50","author":"Benabid A.L.","year":"1987","unstructured":"Benabid A.L., Pollak P., Louveau A., Henry S. and de Rougemont J.: Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50: 344.","journal-title":"Appl Neurophysiol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(80)91680-3","article-title":"Suppression of intention tremor by contingent deep-brain stimulation","volume":"1","author":"Brice J.","year":"1980","unstructured":"Brice J. and McLellan L.: Suppression of intention tremor by contingent deep-brain stimulation. Lancet 1980; 1: 1221.","journal-title":"Lancet"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3171\/2010.4.FOCUS10106"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2741\/4586","article-title":"Deep brain stimulation: foundations and future trends","volume":"23","author":"Aum D.J.","year":"2018","unstructured":"Aum D.J. and Tierney T.S.: Deep brain stimulation: foundations and future trends. Front Biosci (Landmark Ed) 2018; 23: 162.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson's disease","volume":"1","author":"Muller T.","year":"2012","unstructured":"Muller T.: Drug therapy in patients with Parkinson's disease. Transl Neurodegener 2012; 1: 10.","journal-title":"Transl Neurodegener"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-381328-2.00006-7","article-title":"Surgical approach to l-dopa-induced dyskinesias","volume":"98","author":"Sankar T.","year":"2011","unstructured":"Sankar T. and Lozano A.M.: Surgical approach to l-dopa-induced dyskinesias. Int Rev Neurobiol 2011; 98: 151.","journal-title":"Int Rev Neurobiol"},{"key":"e_1_3_3_8_2","first-page":"S34","article-title":"Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease","volume":"55","author":"Kumar R.","year":"2000","unstructured":"Kumar R., Lang A.E., Rodriguez-Oroz M.C., Lozano A.M., Limousin P., Pollak P. et al: Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology 2000; 55: S34.","journal-title":"Neurology"},{"key":"e_1_3_3_9_2","first-page":"1","article-title":"Long-term outcomes following deep brain stimulation for Parkinson's disease","author":"Hitti F.L.","year":"2019","unstructured":"Hitti F.L., Ramayya A.G., McShane B.J., Yang A.I., Vaughan K.A. and Baltuch G.H.: Long-term outcomes following deep brain stimulation for Parkinson's disease. J Neurosurg 2019; : 1.","journal-title":"J Neurosurg"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden C.D.","year":"1976","unstructured":"Marsden C.D. and Parkes J.D.: \u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292.","journal-title":"Lancet"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Stalevo reduction in dyskinesia evaluation in parkinson's disease, factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren Olanow C.","year":"2013","unstructured":"Warren Olanow C., Kieburtz K., Rascol O., Poewe W., Schapira A.H., Emre M. et al: Stalevo reduction in dyskinesia evaluation in parkinson's disease, factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28: 1064.","journal-title":"Mov Disord"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","article-title":"Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial","volume":"13","author":"Volkmann J.","year":"2014","unstructured":"Volkmann J., Mueller J., Deuschl G., Kuhn A.A., Krauss J.K., Poewe W. et al: Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014; 13: 875.","journal-title":"Lancet Neurol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.64.2.170","article-title":"French Stimulation for Tardive dyskinesia study, bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia","volume":"64","author":"Damier P.","year":"2007","unstructured":"Damier P., Thobois S., Witjas T., Cuny E., Derost P., Raoul S. et al: French Stimulation for Tardive dyskinesia study, bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007; 64: 170.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079241","article-title":"Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis","volume":"8","author":"Miquel M.","year":"2013","unstructured":"Miquel M., Spampinato U., Latxague C., Aviles-Olmos I., Bader B., Bertram K. et al: Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis. PLoS ONE 2013; 8: e79241.","journal-title":"PLoS ONE"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(09)70151-6","article-title":"Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study","volume":"8","author":"Vidailhet M.","year":"2009","unstructured":"Vidailhet M., Yelnik J., Lagrange C., Fraix V., Grabli D., Thobois S. et al: Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8: 709.","journal-title":"Lancet Neurol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004295"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2015.00177","article-title":"Surgical approaches working group of the european Huntington's disease, a prospective pilot trial for pallidal deep brain stimulation in huntington's disease","volume":"6","author":"Wojtecki L.","year":"2015","unstructured":"Wojtecki L., Groiss S.J., Ferrea S., Elben S., Hartmann C.J., Dunnett S.B. et al: Surgical approaches working group of the european Huntington's disease, a prospective pilot trial for pallidal deep brain stimulation in huntington's disease. Front Neurol 2015; 6: 177.","journal-title":"Front Neurol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.brs.2014.06.002","article-title":"Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are modulated by psychiatric diagnosis","volume":"7","author":"Eisenstein S.A.","year":"2014","unstructured":"Eisenstein S.A., Dewispelaere W.B., Campbell M.C., Lugar H.M., Perlmutter J.S., Black K.J. et al: Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are modulated by psychiatric diagnosis. Brain Stimul 2014; 7: 701.","journal-title":"Brain Stimul"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00415-016-8314-x","article-title":"Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease","volume":"264","author":"Merola A.","year":"2017","unstructured":"Merola A., Romagnolo A., Rizzi L., Rizzone M.G., Zibetti M., Lanotte M. et al: Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol 2017; 264: 40.","journal-title":"J Neurol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1212\/WNL.0000000000005530","article-title":"Functional movement disorders arising after successful deep brain stimulation","volume":"90","author":"Breen D.P.","year":"2018","unstructured":"Breen D.P., Rohani M., Moro E., Mayberg H.S., Zurowski M., Lozano A.M. et al: Functional movement disorders arising after successful deep brain stimulation. Neurology 2018; 90: 931.","journal-title":"Neurology"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1525"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.03.011"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002005"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3171"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.07.016"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2886"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3950"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.01170.2005"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00245.2003"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.01.002"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2192"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.clinph.2003.12.024","article-title":"Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both","volume":"115","author":"McIntyre C.C.","year":"2004","unstructured":"McIntyre C.C., Savasta M., Kerkerian-Le Goff L. and Vitek J.L.: Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol 2004; 115: 1239.","journal-title":"Clin Neurophysiol"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neubiorev.2006.10.007","article-title":"High frequency deep brain stimulation: what are the therapeutic mechanisms?","volume":"32","author":"Liu Y.","year":"2008","unstructured":"Liu Y., Postupna N., Falkenberg J. and Anderson M.E.: High frequency deep brain stimulation: what are the therapeutic mechanisms?. Neurosci Biobehav Rev 2008; 32: 343.","journal-title":"Neurosci Biobehav Rev"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073858415581986"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.clinph.2008.06.003","article-title":"The clinical utility of methods to determine spatial extent and volume of tissue activated by deep brain stimulation","volume":"119","author":"Gross R.E.","year":"2008","unstructured":"Gross R.E. and Rolston J.D.: The clinical utility of methods to determine spatial extent and volume of tissue activated by deep brain stimulation. Clin Neurophysiol 2008; 119: 1947.","journal-title":"Clin Neurophysiol"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamaneurol.45"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00281.2015"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci6030038","article-title":"Deep brain stimulation in Huntington's disease-preliminary evidence on pathophysiology, efficacy and safety","volume":"6","author":"Wojtecki L.","year":"2016","unstructured":"Wojtecki L., Groiss S.J., Hartmann C.J., Elben S., Omlor S., Schnitzler A. et al: Deep brain stimulation in Huntington's disease-preliminary evidence on pathophysiology, efficacy and safety. Brain Sci 2016; 6.","journal-title":"Brain Sci"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2018.08.008"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4144-11.2013"},{"key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1523\/JNEUROSCI.3523-05.2006","article-title":"Selective attenuation of afferent synaptic transmission as a mechanism of thalamic deep brain stimulation-induced tremor arrest","volume":"26","author":"Anderson T.R.","year":"2006","unstructured":"Anderson T.R., Hu B., Iremonger K. and Kiss Z.H.: Selective attenuation of afferent synaptic transmission as a mechanism of thalamic deep brain stimulation-induced tremor arrest. J Neurosci 2006; 26: 841.","journal-title":"J Neurosci"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2010.07413.x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13649"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.105"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/01616412.2000.11740668","article-title":"Mechanisms of deep brain stimulation and future technical developments","volume":"22","author":"Montgomery E.B.","year":"2000","unstructured":"Montgomery E.B. and Baker K.B.: Mechanisms of deep brain stimulation and future technical developments. Neurol Res 2000; 22: 259.","journal-title":"Neurol Res"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0128-2"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/brain\/awg267","article-title":"Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia","volume":"126","author":"Silberstein P.","year":"2003","unstructured":"Silberstein P., Kuhn A.A., Kupsch A., Trottenberg T., Krauss J.K., Wohrle J.C. et al: Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 2003; 126: 2597.","journal-title":"Brain"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00422-003-0425-7","article-title":"A model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations","volume":"89","author":"Tass P.A.","year":"2003","unstructured":"Tass P.A.: A model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations. Biol Cybern 2003; 89: 81.","journal-title":"Biol Cybern"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006113"},{"key":"e_1_3_3_50_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203782","article-title":"Periodic flashing coordinated reset stimulation paradigm reduces sensitivity to ON and OFF period durations","volume":"13","author":"Tyulmankov D.","year":"2018","unstructured":"Tyulmankov D., Tass P.A. and Bokil H.: Periodic flashing coordinated reset stimulation paradigm reduces sensitivity to ON and OFF period durations. PLoS ONE 2018; 13: e0203782.","journal-title":"PLoS ONE"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(89)90074-X"},{"key":"e_1_3_3_52_2","first-page":"353","article-title":"Microcircuitry of the direct and indirect pathways of the basal ganglia","volume":"86","author":"Smith Y.","year":"1998","unstructured":"Smith Y., Bevan M.D., Shink E. and Bolam J.P.: Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998; 86: 353.","journal-title":"Neuroscience"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009621"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2000.83.3.1760"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3834-08.2008"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2011.00089"},{"key":"e_1_3_3_57_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mds.23502","article-title":"Cortically evoked responses of human pallidal neurons recorded during stereotactic neurosurgery","volume":"26","author":"Nishibayashi H.","year":"2011","unstructured":"Nishibayashi H., Ogura M., Kakishita K., Tanaka S., Tachibana Y., Nambu A. et al: Cortically evoked responses of human pallidal neurons recorded during stereotactic neurosurgery. Mov Disord 2011; 26: 469.","journal-title":"Mov Disord"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1278-13.2013"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11846"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3743"},{"key":"e_1_3_3_61_2","doi-asserted-by":"crossref","unstructured":"Klaus A. J. Alves da Silva and R.M. Costa What If and When to Move: Basal Ganglia Circuits and Self-Paced Action Initiation. Annu Rev Neurosci 2019. 42: p. 459-483.","DOI":"10.1146\/annurev-neuro-072116-031033"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167093"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09159"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.08.028"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4559"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3539-10.2011"},{"key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1523\/JNEUROSCI.2137-12.2013","article-title":"Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models","volume":"33","author":"Cepeda C.","year":"2013","unstructured":"Cepeda C., Galvan L., Holley S.M., Rao S.P., Andre V.M., Botelho E.P. et al: Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. J Neurosci 2013; 33: 7393.","journal-title":"J Neurosci"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10827-009-0196-9"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70223-0"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8351520"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(95)00085-2"},{"key":"e_1_3_3_72_2","unstructured":"Mamad O. and M. Tsanov Brain-computer interface relates hippocampal spatial reconfiguration to the encoding of aversion experience. Society for Neuroscience Meeting 2017. Washington (616): p. 7624."},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/416433a"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5297.213"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3970"},{"key":"e_1_3_3_76_2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41598-017-01067-x","article-title":"Closed-loop deep brain stimulation by pulsatile delayed feedback with increased gap between pulse phases","volume":"7","author":"Popovych O.V.","year":"2017","unstructured":"Popovych O.V., Lysyansky B. and Tass P.A.: Closed-loop deep brain stimulation by pulsatile delayed feedback with increased gap between pulse phases. Sci Rep 2017; 7: 1033.","journal-title":"Sci Rep"},{"key":"e_1_3_3_77_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/acn3.434","article-title":"Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease","volume":"4","author":"Philippens I.","year":"2017","unstructured":"Philippens I., Wubben J.A., Vanwersch R.A.P., Estevao D.L. and Tass P.A.: Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease. Ann Clin Transl Neurol 2017; 4: 585.","journal-title":"Ann Clin Transl Neurol"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-014-0280-3"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.08.023"},{"key":"e_1_3_3_80_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.parkreldis.2016.03.020","article-title":"The adaptive deep brain stimulation challenge","volume":"28","author":"Arlotti M.","year":"2016","unstructured":"Arlotti M., Rosa M., Marceglia S., Barbieri S. and Priori A.: The adaptive deep brain stimulation challenge. Parkinsonism Relat Disord 2016; 28: 12.","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23951"},{"key":"e_1_3_3_82_2","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1523\/JNEUROSCI.1128-16.2016","article-title":"Gamma oscillations in the hyperkinetic state detected with chronic human brain recordings in Parkinson's disease","volume":"36","author":"Swann N.C.","year":"2016","unstructured":"Swann N.C., de Hemptinne C., Miocinovic S., Qasim S., Wang S.S., Ziman N. et al: Gamma oscillations in the hyperkinetic state detected with chronic human brain recordings in Parkinson's disease. J Neurosci 2016; 36: 6445.","journal-title":"J Neurosci"},{"key":"e_1_3_3_83_2","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2552\/aabc9b","article-title":"Adaptive deep brain stimulation for Parkinson's disease using motor cortex sensing","volume":"15","author":"Swann N.C.","year":"2018","unstructured":"Swann N.C., de Hemptinne C., Thompson M.C., Miocinovic S., Miller A.M., Gilron R. et al: Adaptive deep brain stimulation for Parkinson's disease using motor cortex sensing. J Neural Eng 2018; 15: 046006.","journal-title":"J Neural Eng"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0183-z"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06310"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp475"},{"key":"e_1_3_3_87_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/mt.2009.216","article-title":"Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates","volume":"18","author":"Dodiya H.B.","year":"2010","unstructured":"Dodiya H.B., Bjorklund T., Stansell J., Mandel R.J., Kirik D. and Kordower J.H.: Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 2010; 18: 579.","journal-title":"Mol Ther"},{"key":"e_1_3_3_88_2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbrc.2008.02.153","article-title":"Effects on capacitance by overexpression of membrane proteins","volume":"369","author":"Zimmermann D.","year":"2008","unstructured":"Zimmermann D., Zhou A., Kiesel M., Feldbauer K., Terpitz U., Haase W. et al: Effects on capacitance by overexpression of membrane proteins. Biochem Biophys Res Commun 2008; 369: 1022.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.06.004"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60982-9"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182"},{"key":"e_1_3_3_92_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2009.06010.x","article-title":"Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system","volume":"109","author":"McFarland N.R.","year":"2009","unstructured":"McFarland N.R., Lee J.S., Hyman B.T. and McLean P.J.: Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 2009; 109: 838.","journal-title":"J Neurochem"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-071813-104938"},{"key":"e_1_3_3_94_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan E.","year":"2014","unstructured":"Basner-Tschakarjan E. and Mingozzi F.: Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol 2014; 5: 350.","journal-title":"Front Immunol"},{"key":"e_1_3_3_95_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2013.134","article-title":"AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells","volume":"22","author":"Mays L.E.","year":"2014","unstructured":"Mays L.E., Wang L., Lin J., Bell P., Crawford A., Wherry E.J. et al: AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 2014; 22: 28.","journal-title":"Mol Ther"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.109"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"e_1_3_3_98_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors","volume":"5","author":"Tseng Y.S.","year":"2014","unstructured":"Tseng Y.S. and Agbandje-McKenna M.: Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol 2014; 5: 9.","journal-title":"Front Immunol"},{"key":"e_1_3_3_99_2","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1128\/JVI.00675-12","article-title":"Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles","volume":"86","author":"Li C.","year":"2012","unstructured":"Li C., Diprimio N., Bowles D.E., Hirsch M.L., Monahan P.E., Asokan A. et al: Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol 2012; 86: 7752.","journal-title":"J Virol"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00204"},{"key":"e_1_3_3_101_2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yla-Herttuala S.","year":"2012","unstructured":"Yla-Herttuala S.: Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012; 20: 1831.","journal-title":"Mol Ther"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30371-3"},{"key":"e_1_3_3_103_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40291-020-00475-6","article-title":"Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy","volume":"24","author":"Kang C.","year":"2020","unstructured":"Kang C. and Scott L.J.: Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy. Mol Diagn Ther 2020; 24: 487.","journal-title":"Mol Diagn Ther"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70039-4"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1839-17.2017"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00153.2013"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1117\/1.NPh.2.3.031202"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2749"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3210"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.10.016"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2012.07.023"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2996"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2019.04.003"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.02.011"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16046-6"},{"key":"e_1_3_3_118_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1902284116","article-title":"Primate optogenetics: Progress and prognosis","author":"El-Shamayleh Y.","year":"2019","unstructured":"El-Shamayleh Y. and Horwitz G.D.: Primate optogenetics: Progress and prognosis. Proc Natl Acad Sci U S A 2019; .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.024"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193771"},{"key":"e_1_3_3_121_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fnbeh.2015.00166","article-title":"Medial septum regulates the hippocampal spatial representation","volume":"9","author":"Mamad O.","year":"2015","unstructured":"Mamad O., McNamara H.M., Reilly R.B. and Tsanov M.: Medial septum regulates the hippocampal spatial representation. Front Behav Neurosci 2015; 9: 166.","journal-title":"Front Behav Neurosci"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.08.023"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.10.028"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2002365"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1088\/1741-2560\/4\/3\/S02"},{"key":"e_1_3_3_126_2","first-page":"68540H","article-title":"Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons","volume":"6854","author":"Bernstein J.G.","year":"2008","unstructured":"Bernstein J.G., Han X., Henninger M.A., Ko E.Y., Qian X., Franzesi G.T. et al: Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons. Proc SPIE Int Soc Opt Eng 2008; 6854: 68540H.","journal-title":"Proc SPIE Int Soc Opt Eng"},{"key":"e_1_3_3_127_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/hbm.23427","article-title":"Subthalamic nucleus volumes are highly consistent but decrease age-dependently-a combined magnetic resonance imaging and stereology approach in humans","volume":"38","author":"Zwirner J.","year":"2017","unstructured":"Zwirner J., Mobius D., Bechmann I., Arendt T., Hoffmann K.T., Jager C. et al: Subthalamic nucleus volumes are highly consistent but decrease age-dependently-a combined magnetic resonance imaging and stereology approach in humans. Hum Brain Mapp 2017; 38: 909.","journal-title":"Hum Brain Mapp"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2012.08.004"},{"key":"e_1_3_3_129_2","doi-asserted-by":"crossref","first-page":"E7297","DOI":"10.1073\/pnas.1610784113","article-title":"FEF inactivation with improved optogenetic methods","volume":"113","author":"Acker L.","year":"2016","unstructured":"Acker L., Pino E.N., Boyden E.S. and Desimone R.: FEF inactivation with improved optogenetic methods. Proc Natl Acad Sci U S A 2016; 113: E7297.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_3_130_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.physbeh.2004.08.032","article-title":"Modulation of physiological brain hyperthermia by environmental temperature and impaired blood outflow in rats","volume":"83","author":"Kiyatkin E.A.","year":"2004","unstructured":"Kiyatkin E.A. and Brown P.L.: Modulation of physiological brain hyperthermia by environmental temperature and impaired blood outflow in rats. Physiol Behav 2004; 83: 467.","journal-title":"Physiol Behav"},{"key":"e_1_3_3_131_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1567202043480233","article-title":"Brain hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications","volume":"1","author":"Kiyatkin E.A.","year":"2004","unstructured":"Kiyatkin E.A.: Brain hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications. Curr Neurovasc Res 2004; 1: 77.","journal-title":"Curr Neurovasc Res"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3752"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10360"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2836"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15389"},{"key":"e_1_3_3_136_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-015-0031-x","article-title":"CRISPR\/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases","volume":"10","author":"Tu Z.","year":"2015","unstructured":"Tu Z., Yang W., Yan S., Guo X. and Li X.J.: CRISPR\/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Mol Neurodegener 2015; 10: 35.","journal-title":"Mol Neurodegener"},{"key":"e_1_3_3_137_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fnmol.2019.00110","article-title":"Editing the central nervous system through CRISPR\/Cas9 systems","volume":"12","author":"Cota-Coronado A.","year":"2019","unstructured":"Cota-Coronado A., Diaz-Martinez N.F., Padilla-Camberos E. and Diaz-Martinez N.E.: Editing the central nervous system through CRISPR\/Cas9 systems. Front Mol Neurosci 2019; 12: 110.","journal-title":"Front Mol Neurosci"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2649"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2842"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254445"},{"key":"e_1_3_3_141_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/WCO.0b013e32832fd487","article-title":"Emerging genetic therapies to treat Duchenne muscular dystrophy","volume":"22","author":"Nelson S.F.","year":"2009","unstructured":"Nelson S.F., Crosbie R.H., Miceli M.C. and Spencer M.J.: Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009; 22: 532.","journal-title":"Curr Opin Neurol"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.08.019"},{"key":"e_1_3_3_144_2","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin J.W.","year":"2016","unstructured":"Shin J.W., Kim K.H., Chao M.J., Atwal R.S., Gillis T., MacDonald M.E. et al: Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 2016; 25: 4566.","journal-title":"Hum Mol Genet"},{"key":"e_1_3_3_145_2","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang S.","year":"2017","unstructured":"Yang S., Chang R., Yang H., Zhao T., Hong Y., Kong H.E. et al: CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. J Clin Invest 2017; 127: 2719.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.05.010"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0326-x"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-010909-095056"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.11.024"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0478-3"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30280-6"},{"key":"e_1_3_3_152_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","article-title":"Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice","volume":"11","author":"Agustin-Pavon C.","year":"2016","unstructured":"Agustin-Pavon C., Mielcarek M., Garriga-Canut M. and Isalan M.: Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener 2016; 11: 64.","journal-title":"Mol Neurodegener"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/35888"},{"key":"e_1_3_3_154_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-017-0307-1","article-title":"Gene suppression approaches to neurodegeneration","volume":"9","author":"Ghosh R.","year":"2017","unstructured":"Ghosh R. and Tabrizi S.J.: Gene suppression approaches to neurodegeneration. Alzheimers Res Ther 2017; 9: 82.","journal-title":"Alzheimers Res Ther"},{"key":"e_1_3_3_155_2","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010137","article-title":"RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs","volume":"9","author":"Bajan S.","year":"2020","unstructured":"Bajan S. and Hutvagner G.: RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells 2020; 9.","journal-title":"Cells"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2321"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.04.004"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501507102"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.50"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.200"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.219"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv442"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208760"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.53"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.05.006"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.141"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.7"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.14"},{"key":"e_1_3_3_169_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar S.","year":"2017","unstructured":"Aguiar S., van der Gaag B. and Cortese F.A.B.: RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. Transl Neurodegener 2017; 6: 30.","journal-title":"Transl Neurodegener"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.2000.10.117"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"e_1_3_3_173_2","article-title":"Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease","author":"Cole T.A.","year":"2019","unstructured":"Cole T.A., Zhao H., Collier T.J., Sandoval I., Sortwell C.E., Steece-Collier K. et al: Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. BioRxiv 2019; .","journal-title":"BioRxiv"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.08.002"},{"key":"e_1_3_3_175_2","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","article-title":"Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting alpha-synuclein as a novel therapy for Parkinson's disease","volume":"9","author":"Uehara T.","year":"2019","unstructured":"Uehara T., Choong C.J., Nakamori M., Hayakawa H., Nishiyama K., Kasahara Y. et al: Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting alpha-synuclein as a novel therapy for Parkinson's disease. Sci Rep 2019; 9: 7567.","journal-title":"Sci Rep"},{"key":"e_1_3_3_176_2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122768","article-title":"An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis","volume":"4","author":"Gertsman I.","year":"2019","unstructured":"Gertsman I., Wuu J., McAlonis-Downes M., Ghassemian M., Ling K., Rigo F. et al: An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight 2019; 4.","journal-title":"JCI Insight"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70061-9"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002445"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"e_1_3_3_180_2","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"De Vivo, and I.-C.I.-C.S. Groups, Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras B.T.","year":"2019","unstructured":"Darras B.T., Chiriboga C.A., Iannaccone S.T., Swoboda K.J., Montes J., Mignon L. et al: De Vivo, and I.-C.I.-C.S. Groups, Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies. Neurology 2019; 92: e2492.","journal-title":"Neurology"},{"key":"e_1_3_3_181_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim K.R.","year":"2017","unstructured":"Lim K.R., Maruyama R. and Yokota T.: Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 2017; 11: 533.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_3_182_2","doi-asserted-by":"crossref","unstructured":"Scoles D.R. E.V. Minikel and S.M. Pulst Antisense oligonucleotides: A primer. Neurol Genet 2019. 5(2): p. e323.","DOI":"10.1212\/NXG.0000000000000323"},{"key":"e_1_3_3_183_2","doi-asserted-by":"crossref","unstructured":"Dulsat C. American Academy of Neurology - 69th Annual Meeting (April 22-28 2017 - Boston Massachusetts USA). Drugs Today (Barc) 2017. 53(5): p. 309-319.","DOI":"10.1358\/dot.2017.53.5.2646003"},{"key":"e_1_3_3_184_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JHD-189003","article-title":"Huntington's Disease clinical trials corner: august 2018","volume":"7","author":"Rodrigues F.B.","year":"2018","unstructured":"Rodrigues F.B. and Wild E.J.: Huntington's Disease clinical trials corner: august 2018. J Huntingtons Dis 2018; 7: 279.","journal-title":"J Huntingtons Dis"},{"key":"e_1_3_3_185_2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Phase 1\u20132a, Targeting Huntingtin Expression in Patients with Huntington's Disease","volume":"380","author":"Tabrizi S.J.","year":"2019","unstructured":"Tabrizi S.J., Leavitt B.R., Landwehrmeyer G.B., Wild E.J., Saft C., Barker R.A. et al: Phase 1\u20132a, Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med 2019; 380: 2307.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_186_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The effects of 2'-O-methoxyethyl oligonucleotides on renal function in humans","volume":"28","author":"Crooke S.T.","year":"2018","unstructured":"Crooke S.T., Baker B.F., Pham N.C., Hughes S.G., Kwoh T.J., Cai D. et al: The effects of 2'-O-methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid Ther 2018; 28: 10.","journal-title":"Nucleic Acid Ther"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1910-4"},{"key":"e_1_3_3_188_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2017.00011","article-title":"Molecular imaging markers to track huntington's disease pathology","volume":"8","author":"Wilson H.","year":"2017","unstructured":"Wilson H., De Micco R., Niccolini F. and Politis M.: Molecular imaging markers to track huntington's disease pathology. Front Neurol 2017; 8: 11.","journal-title":"Front Neurol"},{"key":"e_1_3_3_189_2","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0423-17.2019","article-title":"Extrafield activity shifts the place field center of mass to encode aversive experience","volume":"6","author":"Mamad O.","year":"2019","unstructured":"Mamad O., Agayby B., Stumpp L., Reilly R.B. and Tsanov M.: Extrafield activity shifts the place field center of mass to encode aversive experience. eNeuro 2019; 6.","journal-title":"eNeuro"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037020304797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037020304797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2020.11.012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:34:11Z","timestamp":1779021251000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2020.11.012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":188,"alternative-id":["10.1016\/j.csbj.2020.11.012"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2020.11.012","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurons under genetic control: What are the next steps towards the treatment of movement disorders?","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}